CAJ | 학술논문

目的观察派罗欣联合解毒升白颗粒治疗慢乙肝患者的临床疗效以及不良反应.方法选择符合干扰素应用指征的慢性乙型肝炎患者112例,分为治疗组和对照组两组,每组各56例,分别给予派罗欣联合解毒升白颗粒及派罗欣治疗,比较治疗前后两组中医证候积分；观察两组治疗12周、24周、36周、48周及停药后24周HBeAg转阴率、HBeAg/抗HBe转换率及HBV DNA转阴率及主要不良反应并进行比较.结果治疗48周后,治疗组症状改善(总有效率96.4％)优于对照组(总有效率85.7％)；治疗组治疗48周HBeAg转阴率(54.8％)、HBeAg/抗HBe转换率(48.4％)及HBV DNA转阴率(62.5％)高于对照组(分别为28.1％,21.9％,42.9％),两组比较差异有统计学意义(P＜0.05)；治疗组血液学不良反应(89例次)明显低于对照组(165例次),差异有统计学意义(P＜0.05).结论派罗欣联合解毒升白颗粒治疗慢性乙型肝炎可改善临床症状、提高临床疗效,减少派罗欣的不良反应.
목적 관찰파라흔연합해독승백과립치료만을간환자적림상료효이급불량반응.방법 선택부합간우소응용지정적만성을형간염환자112례,분위치료조화대조조량조,매조각56례,분별급여파라흔연합해독승백과립급파라흔치료,비교치료전후량조중의증후적분；관찰량조치료12주、24주、36주、48주급정약후24주HBeAg전음솔、HBeAg/항HBe전환솔급HBV DNA전음솔급주요불량반응병진행비교.결과 치료48주후,치료조증상개선(총유효솔96.4％)우우대조조(총유효솔85.7％)；치료조치료48주HBeAg전음솔(54.8％)、HBeAg/항HBe전환솔(48.4％)급HBV DNA전음솔(62.5％)고우대조조(분별위28.1％,21.9％,42.9％),량조비교차이유통계학의의(P＜0.05)；치료조혈액학불량반응(89례차)명현저우대조조(165례차),차이유통계학의의(P＜0.05).결론 파라흔연합해독승백과립치료만성을형간염가개선림상증상、제고림상료효,감소파라흔적불량반응.
Objective To investigate the clinical effects and adverse reactions of Peginterferon α-2a in combination with Jiedushengbai granule in the treatment of patients with chronic hepatitis B.Methods 112 patients with chronic hepatitis B who were suitable for treatment of interferon were selected and divided into study group and control group,and each group had 56 patients.The study group received Peginterferon α-2a in combination with Jiedushengbai granule and the control group was treated with Peginterferon α-2a alone.The score of Chinese traditional medicine symptoms,rate of negative conversion of HBeAg and HBV DNA,conversion of HBeAg/anti-HBe at the 12th,24th,36th,48th week after treatment and the 24th week after completion of medication were recorded and compared between the two groups.Results 48 weeks after drug administration the symptoms of patients in the study group (overall response rate 96.4％ ) were significantly improved compared with the control group ( overall response rate 85.7％ ).Rate of negative conversion of HBeAg and HBV DNA,conversion of HBeAg/anti-HBe at the 48th week after treatment in the study group were 54.8％,48.4％ and 62.5％,significantly higher than those in the control group(28.1％,21.9％ and 42.9％,P ＜ 0.05). The serum adverse reactions in the study group were 89 events,significantly fewer than those in the control group( 165 events,P ＜ 0.05 ).Conclusion Peginterferon α-2a in combination with Jiedushengbai granule could improve the clinical symptoms and clinical effects and reduce adverse reactions related to Peginterferon α-2a.